Nils Schröter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nils Schröter has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
Michel Rijntjes
17 shared publicationsHorst Urbach
13 shared publications- Alexander Rau
Department of Neuroradiology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
11 shared publications Cornelius Weiller
Department of Neurology and Clinical Neuroscience, Medical Center—University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany
10 shared publications- Lars Frings
Department of Nuclear Medicine, Medical Center - Faculty of Medicine, University of Freiburg, Freiburg, Germany
8 shared publications Marco Reisert
8 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 152
Nigrostriatal free-water imaging and volumetry outperform quantitative T1 in neurodegenerative Parkinson syndromes
- 7 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 152
Open AccessNigrostriatal free-water imaging and volumetry outperform quantitative T1 in neurodegenerative Parkinson syndromes
- Open Access
- 26 June 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1241-1249
Abnormal motor control effort costs in Parkinson's disease patients with apathy
Background: In Parkinson's disease, abnormalities in reward-effort trade-offs are thought to underlie both apathy and bradykinesia. However, it remains unclear whether effort cost computations contribute to these symptoms independently of reward, and which exact effort costs are involved. Objective: To assess whether effort-based decision-making in the absence of any explicit rewards differs between Parkinson patients and healthy controls and to explore whether putative differences are related to apathy or bradykinesia. Methods: To address this, we developed a novel decision-making task that isolated physical effort costs from reward processing. Twenty-one Parkinson patients tested on and off dopaminergic medication, and 20 healthy participants, had to choose between two options that differed only in their requirements of force effort, either requiring larger total amounts of force or greater changes in force. We quantified participants’ preference for these different effort types and their sensitivity to changes in relative effort. Results: Patients differed from healthy participants in both overall effort preference ( P = 0.009) and sensitivity to changing efforts ( P = 0.036), being more likely to choose options requiring overall lower force levels and more influenced by increasing requirements of changes in force. These effects were unaffected by dopaminergic medication. Importantly, sensitivity to increasing requirements for changes in force was associated with apathy ( P = 0.004), but not bradykinesia. Conclusion: Our findings suggest that, beyond well-known diminished responses to potential rewards, apathy in Parkinson's disease is related to aberrant effort cost computations, in particular those involving dynamic changes in movement, during decision-making.
- 26 June 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1241-1249
Open AccessAbnormal motor control effort costs in Parkinson's disease patients with apathy
Background: In Parkinson's disease, abnormalities in reward-effort trade-offs are thought to underlie both apathy and bradykinesia. However, it remains unclear whether effort cost computations contribute to these symptoms independently of reward, and which exact effort costs are involved. Objective: To assess whether effort-based decision-making in the absence of any explicit rewards differs between Parkinson patients and healthy controls and to explore whether putative differences are related to apathy or bradykinesia. Methods: To address this, we developed a novel decision-making task that isolated physical effort costs from reward processing. Twenty-one Parkinson patients tested on and off dopaminergic medication, and 20 healthy participants, had to choose between two options that differed only in their requirements of force effort, either requiring larger total amounts of force or greater changes in force. We quantified participants’ preference for these different effort types and their sensitivity to changes in relative effort. Results: Patients differed from healthy participants in both overall effort preference ( P = 0.009) and sensitivity to changing efforts ( P = 0.036), being more likely to choose options requiring overall lower force levels and more influenced by increasing requirements of changes in force. These effects were unaffected by dopaminergic medication. Importantly, sensitivity to increasing requirements for changes in force was associated with apathy ( P = 0.004), but not bradykinesia. Conclusion: Our findings suggest that, beyond well-known diminished responses to potential rewards, apathy in Parkinson's disease is related to aberrant effort cost computations, in particular those involving dynamic changes in movement, during decision-making.
- Open Access
- 27 April 2026
- Published by Springer Nature in Neurological Research and Practice
- Vol. 8 (1) , 32
Protocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE Trial
INSPIRE-PNRM+ (short for InterdiSciPlinary and InteRsectoral telemedIcal Evaluation, Coordination and Therapy at the ParkinsonNet RheinMain+) is an one-year, multicentre, interventional, open-label, two-arm, 1:1 randomized controlled trial (RCT) with the goal to improve the quality of care for Parkinson’s disease (PD) patients outside of a specialized clinical context. The study is funded by the German Innovation Fund mandated by the Federal Joint Committee (G-BA). The three core characteristics are (1) the employment of specially trained advanced practice nurses (APN) in an (2) interdisciplinary network and (3) the use of a specifically designed digital platform. This platform serves for documentation and communication, thereby helping patients receive individualized, guideline-based treatment and support in adapting their lives to the effects of the disease. 844 patients will be recruited. They will be divided into two groups: a “usual care” group which continues traditional care (i.e., usually consultation with a neurologist in private practice) vs. the “intervention” group which will have APN contact every three months or more frequently as needed over the period of 12 months. Patients’ quality of life serves as primary outcome measure, combined with a process evaluation and health economic analysis (cost-utility analysis (CUA)). Recruitment was ongoing at time of submission of this paper. This innovative study is the first in Germany where APNs are dedicated to PD care. The study may serve as blueprint when incorporating APNs into routine healthcare, similar to other countries. Trial registration: The study has been registered at www.clinicaltrials.gov , NCT06479083. Registered June 27, 2024. https://clinicaltrials.gov/study/NCT06479083?term=INSPIRE%20Parkinson&rank=1 .
- 27 April 2026
- Published by Springer Nature in Neurological Research and Practice
- Vol. 8 (1) , 32
Open AccessProtocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE Trial
INSPIRE-PNRM+ (short for InterdiSciPlinary and InteRsectoral telemedIcal Evaluation, Coordination and Therapy at the ParkinsonNet RheinMain+) is an one-year, multicentre, interventional, open-label, two-arm, 1:1 randomized controlled trial (RCT) with the goal to improve the quality of care for Parkinson’s disease (PD) patients outside of a specialized clinical context. The study is funded by the German Innovation Fund mandated by the Federal Joint Committee (G-BA). The three core characteristics are (1) the employment of specially trained advanced practice nurses (APN) in an (2) interdisciplinary network and (3) the use of a specifically designed digital platform. This platform serves for documentation and communication, thereby helping patients receive individualized, guideline-based treatment and support in adapting their lives to the effects of the disease. 844 patients will be recruited. They will be divided into two groups: a “usual care” group which continues traditional care (i.e., usually consultation with a neurologist in private practice) vs. the “intervention” group which will have APN contact every three months or more frequently as needed over the period of 12 months. Patients’ quality of life serves as primary outcome measure, combined with a process evaluation and health economic analysis (cost-utility analysis (CUA)). Recruitment was ongoing at time of submission of this paper. This innovative study is the first in Germany where APNs are dedicated to PD care. The study may serve as blueprint when incorporating APNs into routine healthcare, similar to other countries. Trial registration: The study has been registered at www.clinicaltrials.gov , NCT06479083. Registered June 27, 2024. https://clinicaltrials.gov/study/NCT06479083?term=INSPIRE%20Parkinson&rank=1 .
- 27 February 2026
- Published by Springer Nature in Die Radiologie
- Vol. 66 (4) , 241-248
MRT-Bildgebung bei neurodegenerativen Parkinson-Syndromen
Zusammenfassung Hintergrund Die Parkinson-Krankheit (PK) und die atypischen Parkinsonsyndrome (APS) Multisystematrophie (MSA), progressive supranukleäre Blickparese (PSP) und kortikobasale Degeneration (CBD) nehmen weltweit an Prävalenz zu. Eine frühzeitige differenzialdiagnostische Einordnung ist herausfordernd, da Symptome überlappen und pathognomonische Zeichen oft erst spät auftreten. Ziel der Arbeit Darstellung der Rolle der strukturellen Magnetresonanztomographie (MRT) in der Differenzialdiagnostik neurodegenerativer Parkinson-Syndrome. Material und Methoden Literaturanalyse aktueller Leitlinien und Studien zu T1-, T2-gewichteten Sequenzen, suszeptibilitätsgewichteter Bildgebung (SWI), diffusionsgewichteten Aufnahmen, Volumetrie und multiparametrischen Ansätzen. Besonderes Augenmerk liegt auf krankheitstypischen Atrophiemustern, quantitativen Methoden und automatisierten Auswertungen. Ergebnisse Bei der PK sind strukturelle Veränderungen meist subtil; das Schwalbenschwanz-Zeichen in der SWI kann Hinweise auf das Vorliegen eines neurodegenerativen Parkinson-Syndroms geben. Die PSP zeichnet sich durch eine Mittelhirnatrophie aus. Die MSA weist je nach Subtyp eine Putamen- bzw. zerebellopontin akzentuierte Atrophie auf. CBD zeigt asymmetrische kortikale Atrophie insbesondere der Zentralregion. Volumetrie und multiparametrische Analysen erhöhen die diagnostische Genauigkeit insbesondere in frühen Krankheitsstadien, während die Translation in die klinische Routine noch begrenzt ist. Diskussion Strukturelle MRT liefert frühzeitig Hinweise auf APS und unterstützt die Differenzialdiagnose. Quantitative und multiparametrische Methoden verbessern die Objektivität und Sensitivität, insbesondere bei subtilen oder selteneren Syndromen, und könnten zukünftig eine wichtige Rolle in der klinischen Praxis spielen.
- 27 February 2026
- Published by Springer Nature in Die Radiologie
- Vol. 66 (4) , 241-248
MRT-Bildgebung bei neurodegenerativen Parkinson-Syndromen
Zusammenfassung Hintergrund Die Parkinson-Krankheit (PK) und die atypischen Parkinsonsyndrome (APS) Multisystematrophie (MSA), progressive supranukleäre Blickparese (PSP) und kortikobasale Degeneration (CBD) nehmen weltweit an Prävalenz zu. Eine frühzeitige differenzialdiagnostische Einordnung ist herausfordernd, da Symptome überlappen und pathognomonische Zeichen oft erst spät auftreten. Ziel der Arbeit Darstellung der Rolle der strukturellen Magnetresonanztomographie (MRT) in der Differenzialdiagnostik neurodegenerativer Parkinson-Syndrome. Material und Methoden Literaturanalyse aktueller Leitlinien und Studien zu T1-, T2-gewichteten Sequenzen, suszeptibilitätsgewichteter Bildgebung (SWI), diffusionsgewichteten Aufnahmen, Volumetrie und multiparametrischen Ansätzen. Besonderes Augenmerk liegt auf krankheitstypischen Atrophiemustern, quantitativen Methoden und automatisierten Auswertungen. Ergebnisse Bei der PK sind strukturelle Veränderungen meist subtil; das Schwalbenschwanz-Zeichen in der SWI kann Hinweise auf das Vorliegen eines neurodegenerativen Parkinson-Syndroms geben. Die PSP zeichnet sich durch eine Mittelhirnatrophie aus. Die MSA weist je nach Subtyp eine Putamen- bzw. zerebellopontin akzentuierte Atrophie auf. CBD zeigt asymmetrische kortikale Atrophie insbesondere der Zentralregion. Volumetrie und multiparametrische Analysen erhöhen die diagnostische Genauigkeit insbesondere in frühen Krankheitsstadien, während die Translation in die klinische Routine noch begrenzt ist. Diskussion Strukturelle MRT liefert frühzeitig Hinweise auf APS und unterstützt die Differenzialdiagnose. Quantitative und multiparametrische Methoden verbessern die Objektivität und Sensitivität, insbesondere bei subtilen oder selteneren Syndromen, und könnten zukünftig eine wichtige Rolle in der klinischen Praxis spielen.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2026 (1)
Cerebral Manifestation of Miliary Tuberculosis Mimicking a Parasitic CNS Infection
The neuroradiological findings of central nervous system (CNS) manifestations of miliary tuberculosis can be misinterpreted as parasitic infections due to their low prevalence in the European population. We present the case of a 30‐year‐old woman in whom CNS tuberculosis was initially misdiagnosed as a parasitic infection due to the absence of pulmonary symptoms. She immigrated to Germany from Madagascar and had lived in Europe for 14 months by the time she presented to our department with an incidental MRI finding suggestive of a manifestation of toxoplasmosis. The T1‐weighted axial brain MRI scan revealed multifocal, rim‐enhancing lesions that were suggestive of parasitic infection. Following a chest CT scan that revealed miliary tuberculosis, the diagnosis was revised to neurotuberculosis. This was confirmed by a polymerase chain reaction (PCR) that detected the Mycobacterium tuberculosis complex in the sputum sample. The patient achieved remission following 12 months of antituberculosis therapy. In conclusion, neurotuberculosis should be considered in the differential diagnosis of infections presenting with multifocal CNS manifestations on neuroimaging scans in European patients, particularly those with a migration background.
- 1 January 2026
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2026 (1)
Open AccessCerebral Manifestation of Miliary Tuberculosis Mimicking a Parasitic CNS Infection
The neuroradiological findings of central nervous system (CNS) manifestations of miliary tuberculosis can be misinterpreted as parasitic infections due to their low prevalence in the European population. We present the case of a 30‐year‐old woman in whom CNS tuberculosis was initially misdiagnosed as a parasitic infection due to the absence of pulmonary symptoms. She immigrated to Germany from Madagascar and had lived in Europe for 14 months by the time she presented to our department with an incidental MRI finding suggestive of a manifestation of toxoplasmosis. The T1‐weighted axial brain MRI scan revealed multifocal, rim‐enhancing lesions that were suggestive of parasitic infection. Following a chest CT scan that revealed miliary tuberculosis, the diagnosis was revised to neurotuberculosis. This was confirmed by a polymerase chain reaction (PCR) that detected the Mycobacterium tuberculosis complex in the sputum sample. The patient achieved remission following 12 months of antituberculosis therapy. In conclusion, neurotuberculosis should be considered in the differential diagnosis of infections presenting with multifocal CNS manifestations on neuroimaging scans in European patients, particularly those with a migration background.
- Open Access
- 12 May 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (11) , 1655-1664
Neuroimaging in advanced Parkinson’s disease: insights into pathophysiology, biomarkers, and personalized therapies
Advanced Parkinson’s disease (APD) represents a late stage of Parkinson’s disease and is characterized by complex motor and non-motor symptoms that are less responsive to oral dopaminergic therapies. While APD has a relevant impact on patients’ quality of life and requires intensified treatment, consistent diagnostic criteria have only recently been proposed. The precise pathophysiology underlying the symptoms of APD remains poorly understood, making early prognostication and intervention difficult. Neuroimaging has emerged as a promising tool for elucidating the mechanisms driving APD, identifying biomarkers for disease staging, and predicting therapeutic response. Techniques such as molecular imaging and magnetic resonance imaging provide insight into molecular and structural changes associated with the progression of PD, including protein aggregation, neuroinflammation, and regional neurodegeneration. While positron emission tomography imaging of alpha-synuclein and other pathologies offers avenues for staging and differential diagnosis, advanced magnetic resonance imaging approaches have the potential for capturing subtle microstructural changes i.e. through neuromelanin-sensitive or diffusion-weighted imaging. However, the majority of imaging studies has focused on early Parkinson’s disease, leaving their applicability to APD uncertain. Future research should prioritize the validation of neuroimaging findings in well-defined APD cohorts and extend their use to predict clinical milestones such as motor fluctuations, dyskinesia, and cognitive decline. These efforts are essential to advance personalized therapeutic strategies and bridge the gap between research and clinical management of APD.
- 12 May 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (11) , 1655-1664
Open AccessNeuroimaging in advanced Parkinson’s disease: insights into pathophysiology, biomarkers, and personalized therapies
Advanced Parkinson’s disease (APD) represents a late stage of Parkinson’s disease and is characterized by complex motor and non-motor symptoms that are less responsive to oral dopaminergic therapies. While APD has a relevant impact on patients’ quality of life and requires intensified treatment, consistent diagnostic criteria have only recently been proposed. The precise pathophysiology underlying the symptoms of APD remains poorly understood, making early prognostication and intervention difficult. Neuroimaging has emerged as a promising tool for elucidating the mechanisms driving APD, identifying biomarkers for disease staging, and predicting therapeutic response. Techniques such as molecular imaging and magnetic resonance imaging provide insight into molecular and structural changes associated with the progression of PD, including protein aggregation, neuroinflammation, and regional neurodegeneration. While positron emission tomography imaging of alpha-synuclein and other pathologies offers avenues for staging and differential diagnosis, advanced magnetic resonance imaging approaches have the potential for capturing subtle microstructural changes i.e. through neuromelanin-sensitive or diffusion-weighted imaging. However, the majority of imaging studies has focused on early Parkinson’s disease, leaving their applicability to APD uncertain. Future research should prioritize the validation of neuroimaging findings in well-defined APD cohorts and extend their use to predict clinical milestones such as motor fluctuations, dyskinesia, and cognitive decline. These efforts are essential to advance personalized therapeutic strategies and bridge the gap between research and clinical management of APD.
- Open Access
- 9 April 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107827
Amygdala neurodegeneration differentiates brain-first and body-first Parkinson's disease: An MRI study
- 9 April 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107827
Open AccessAmygdala neurodegeneration differentiates brain-first and body-first Parkinson's disease: An MRI study
- Open Access
- 4 March 2025
- Published by Elsevier in Neuroimage: Reports
- Vol. 5 (1) , 100247
Domain-specific brain regions are associated with cognitive impairment in progressive supranuclear palsy
- 4 March 2025
- Published by Elsevier in Neuroimage: Reports
- Vol. 5 (1) , 100247
Open AccessDomain-specific brain regions are associated with cognitive impairment in progressive supranuclear palsy
- 24 February 2025
- Published by Oxford University Press (OUP) in Brain
Hippocampus and basal forebrain degeneration differentially impact cognition in Lewy body spectrum disorders
Cognitive impairment is a major contributor to the burden in Parkinson’s disease and dementia with Lewy bodies, both of which make up the Lewy body disease spectrum, with dementia affecting up to 80% of patients over the course of the disease. Macroatrophy and microstructural neurodegenerative alterations are typically assessed separately in MRI, although neuropathologically they represent the same mechanism—the loss of functional tissue. To gain a deeper insight into the differential impact of neurodegeneration in the basal forebrain and hippocampus on cognition, we have developed a combined volumetric-mesoscopic approach to more comprehensively quantify the extent of neurodegeneration. This approach might facilitate a more profound understanding of cognitive decline. We report a retrospective analysis of MRI data from 147 patients with Lewy body disease (Parkinson’s disease with normal cognition = 50, with mild cognitive impairment = 59, with dementia = 25 and 13 patients with dementia with Lewy bodies) and 30 healthy controls. Neurodegeneration of the basal forebrain and hippocampus was quantified by assessing the total macrostructural volume and microstructural metrics. Additionally, these parameters were combined to evaluate the potential of the functional volume for capturing the coinciding pathophysiological processes. The extent of neurodegeneration was compared between healthy controls, patients with normal cognition, mild impaired cognition and dementia. Furthermore, the integrity of the basal forebrain and hippocampus was tested for associations with subdomains of cognitive performance as assessed with the Mattis Dementia Rating Scale 2. Our results revealed significant macro- and microstructural degeneration in the basal forebrain and hippocampus in patients with Parkinson’s disease dementia and dementia with Lewy bodies when compared with healthy controls or Lewy body disease without dementia. Combining volumetric and microstructural metrics to calculate the functional volume provided the strongest effects across cognitive function in Lewy body disease. Moreover, in a combined model of basal forebrain and hippocampus, degeneration of the basal forebrain only was significantly associated with impaired initiation (P = 0.003) and trend-level linked to attention (P = 0.06), whereas hippocampal integrity significantly determined memory (P = 0.005) and conceptualization at trend level (P = 0.06). Combining macro- and microstructural techniques to investigate the functional volume of the basal forebrain and hippocampus revealed that basal forebrain and hippocampal integrity is altered only in Lewy body disease with dementia but not in Lewy body disease with normal cognition or mild cognitive impairment. Moreover, the basal forebrain and hippocampus were differentially associated with distinct neurocognitive domains, thus providing an intriguing biomarker for neurocognitive staging in Lewy body disease or individualized treatment concepts.
- 24 February 2025
- Published by Oxford University Press (OUP) in Brain
Hippocampus and basal forebrain degeneration differentially impact cognition in Lewy body spectrum disorders
Cognitive impairment is a major contributor to the burden in Parkinson’s disease and dementia with Lewy bodies, both of which make up the Lewy body disease spectrum, with dementia affecting up to 80% of patients over the course of the disease. Macroatrophy and microstructural neurodegenerative alterations are typically assessed separately in MRI, although neuropathologically they represent the same mechanism—the loss of functional tissue. To gain a deeper insight into the differential impact of neurodegeneration in the basal forebrain and hippocampus on cognition, we have developed a combined volumetric-mesoscopic approach to more comprehensively quantify the extent of neurodegeneration. This approach might facilitate a more profound understanding of cognitive decline. We report a retrospective analysis of MRI data from 147 patients with Lewy body disease (Parkinson’s disease with normal cognition = 50, with mild cognitive impairment = 59, with dementia = 25 and 13 patients with dementia with Lewy bodies) and 30 healthy controls. Neurodegeneration of the basal forebrain and hippocampus was quantified by assessing the total macrostructural volume and microstructural metrics. Additionally, these parameters were combined to evaluate the potential of the functional volume for capturing the coinciding pathophysiological processes. The extent of neurodegeneration was compared between healthy controls, patients with normal cognition, mild impaired cognition and dementia. Furthermore, the integrity of the basal forebrain and hippocampus was tested for associations with subdomains of cognitive performance as assessed with the Mattis Dementia Rating Scale 2. Our results revealed significant macro- and microstructural degeneration in the basal forebrain and hippocampus in patients with Parkinson’s disease dementia and dementia with Lewy bodies when compared with healthy controls or Lewy body disease without dementia. Combining volumetric and microstructural metrics to calculate the functional volume provided the strongest effects across cognitive function in Lewy body disease. Moreover, in a combined model of basal forebrain and hippocampus, degeneration of the basal forebrain only was significantly associated with impaired initiation (P = 0.003) and trend-level linked to attention (P = 0.06), whereas hippocampal integrity significantly determined memory (P = 0.005) and conceptualization at trend level (P = 0.06). Combining macro- and microstructural techniques to investigate the functional volume of the basal forebrain and hippocampus revealed that basal forebrain and hippocampal integrity is altered only in Lewy body disease with dementia but not in Lewy body disease with normal cognition or mild cognitive impairment. Moreover, the basal forebrain and hippocampus were differentially associated with distinct neurocognitive domains, thus providing an intriguing biomarker for neurocognitive staging in Lewy body disease or individualized treatment concepts.
- Open Access
- 29 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 667
Rebound Tremor Frequency as a Potential Diagnostic Marker for Delayed Therapy Escape after Thalamic Deep Brain Stimulation for Essential Tremor—Insights from a Cross-Sectional Study
Delayed therapy escape (DTE) is frequent after thalamic deep brain stimulation for essential tremor, leading to reduced quality of life, often with ataxic symptoms, and early recognition is challenging. Our goal was to examine whether a low-frequency rebound tremor of the left hand after switching off stimulation is useful as a diagnostic marker for DTE. In this cross-sectional study with additional retrospective analysis, we examined 31 patients with bilateral thalamic DBS ≥ 12 months for essential tremor, using quantitative assessments including video-based motion capture, Fahn–Tolosa–Marin Tremor Rating Scale (FTMTRS), and scale for the assessment and rating of ataxia (SARA). If available, preoperative (preOP) and 12-month postoperative assessments were included in the analysis. Evaluations occurred with DBS activated (ON) and deactivated (OFF). A higher ratio FTMTRS nowON/preOP indicated DTE. Preoperative FTMTRS scores were available for 16 patients, including 5 patients with DTE. The receiver operating characteristic analysis found an area under the curve of 0.86 (p = 0.024) for identification of DTE by low-frequency rebound tremor (i.e., OFF) on the left. In conclusion, it could serve as a potential diagnostic marker.
- 29 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 667
Open AccessRebound Tremor Frequency as a Potential Diagnostic Marker for Delayed Therapy Escape after Thalamic Deep Brain Stimulation for Essential Tremor—Insights from a Cross-Sectional Study
Delayed therapy escape (DTE) is frequent after thalamic deep brain stimulation for essential tremor, leading to reduced quality of life, often with ataxic symptoms, and early recognition is challenging. Our goal was to examine whether a low-frequency rebound tremor of the left hand after switching off stimulation is useful as a diagnostic marker for DTE. In this cross-sectional study with additional retrospective analysis, we examined 31 patients with bilateral thalamic DBS ≥ 12 months for essential tremor, using quantitative assessments including video-based motion capture, Fahn–Tolosa–Marin Tremor Rating Scale (FTMTRS), and scale for the assessment and rating of ataxia (SARA). If available, preoperative (preOP) and 12-month postoperative assessments were included in the analysis. Evaluations occurred with DBS activated (ON) and deactivated (OFF). A higher ratio FTMTRS nowON/preOP indicated DTE. Preoperative FTMTRS scores were available for 16 patients, including 5 patients with DTE. The receiver operating characteristic analysis found an area under the curve of 0.86 (p = 0.024) for identification of DTE by low-frequency rebound tremor (i.e., OFF) on the left. In conclusion, it could serve as a potential diagnostic marker.